Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the stock. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research report on Friday, November 8th. William Blair reissued a “market perform” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Guggenheim reaffirmed a “neutral” rating on shares of Revance Therapeutics in a research report on Monday, August 12th. Piper Sandler downgraded Revance Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, August 12th. Finally, Stifel Nicolaus lowered their price objective on Revance Therapeutics from $24.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.66.

Revance Therapeutics Trading Down 3.2 %

Shares of Revance Therapeutics stock opened at $4.17 on Monday. The company has a fifty day moving average price of $5.41 and a 200 day moving average price of $4.44. Revance Therapeutics has a twelve month low of $2.30 and a twelve month high of $9.74. The stock has a market cap of $437.44 million, a price-to-earnings ratio of -2.16 and a beta of 0.95.

Revance Therapeutics (NASDAQ:RVNC) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. Analysts forecast that Revance Therapeutics will post -1.54 earnings per share for the current year.

Institutional Trading of Revance Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of RVNC. Wellington Management Group LLP acquired a new position in Revance Therapeutics in the third quarter worth $2,315,000. State Street Corp boosted its holdings in shares of Revance Therapeutics by 6.6% in the 3rd quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock valued at $12,632,000 after buying an additional 150,323 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Revance Therapeutics by 11.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 265,210 shares of the biopharmaceutical company’s stock valued at $1,376,000 after buying an additional 27,420 shares during the period. FORA Capital LLC bought a new stake in shares of Revance Therapeutics during the 3rd quarter valued at about $54,000. Finally, FMR LLC raised its stake in Revance Therapeutics by 28.6% during the third quarter. FMR LLC now owns 214,596 shares of the biopharmaceutical company’s stock worth $1,114,000 after acquiring an additional 47,768 shares during the period. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.